Nivalis Therapeutics, Inc.

Rivus Pharmaceuticals Inc. already had its lead Controlled Metabolic Accelerator (CMA), known as HU6, in a Phase IIa clinical trial last year when it raised $35m in series A venture capital. Now, wit

Who: AbbVie Inc./Alpine Immune Sciences What: Potentially adding to its pipeline in immunology, AbbVie obtains an option to acquire ALPN-101, a Phase II-ready candidate for systemic lupus erythemat

The ongoing US government shutdown means that the Securities and Exchange Commission (SEC) can't process new filings for proposed stock offerings, which means that the usual rush of biopharmaceutical

Biopharma start-up fundraising more than doubled to $3.87bn in the second quarter versus the prior quarter, helped by initial public offerings, including the Actelion Pharmaceuticals Ltd. spinout